Skip to main content

Table 3 Conductance catheter derived parameters of right ventricular function in animals subjected to acute pulmonary hypertension

From: Effects of inhaled iloprost on right ventricular contractility, right ventriculo-vascular coupling and ventricular interdependence: a randomized placebo-controlled trial in an experimental model of acute pulmonary hypertension

Parameter

Treatment

Baseline

Pulmonary hypertension

   

Pre-inhalation

5 minutes after inhalation

REF (%)

Iloprost

62 ± 7

50 ± 8*

53 ± 8* ‡

 

Control

54 ± 10

40 ± 11*

37 ± 10*

Ï„/RR

Iloprost

0.08 ± 0.01

0.08 ± 0.01

0.09 ± 0.01†

 

Control

0.07 ± 0.01

0.07 ± 0.01

0.07 ± 0.01

β (ml-1)

Iloprost

0.02 ± 0.01

0.02 ± 0.01

0.02 ± 0.01

 

Control

0.02 ± 0.02

0.02 ± 0.01

0.02 ± 0.01

C (ml/mmHg)

Iloprost

2.29 ± 0.49

1.28 ± 0.33*

1.89 ± 0.64†

 

Control

2.11 ± 0.93

1.08 ± 0.33*

1.11 ± 0.33*

Emax/Ea

Iloprost

1.12 ± 0.11

1.29 ± 0.29

1.03 ± 0.15

 

Control

1.11 ± 0.46

1.01 ± 0.31

0.97 ± 0.33

  1. Values are shown for baseline and in pulmonary hypertension before inhalation and 5 minutes after inhalation of either iloprost or control. For the complete experimental time course, see Additional file 4. Values are expressed as mean ± standard deviation. *P < 0.05 versus baseline; †P < 0.05 versus before inhalation; ‡P < 0.05 iloprost versus control (corrected for multiple comparisons). β = chamber stiffness constant of end-diastolic pressure volume relationship; C, pulmonary artery compliance; Emax/Ea, ratio of the slope of the end-systolic pressure-volume relationship to effective pulmonary arterial elastance; REF, right ventricular ejection fraction; τ/RR, time constant of ventricular relaxation, corrected for the RR interval.